Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging
| Autor: | Bing-Shen Huang, Ying-Chieh Lai, Yi-Wen Fang, Shen-Yen Lin, Gigin Lin, Ti-Yung Tseng, Chun-Bing Chen, Jeng-Hwei Tseng |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Gadolinium DTPA
medicine.medical_specialty Gadoxetic acid Cirrhosis Urology medicine.medical_treatment Renal function Contrast Media Kidney 030218 nuclear medicine & medical imaging Nephrogenic Fibrosing Dermopathy 03 medical and health sciences 0302 clinical medicine Risk Factors medicine Humans Radiology Nuclear Medicine and imaging Dialysis Retrospective Studies Radiological and Ultrasound Technology medicine.diagnostic_test business.industry Gastroenterology Magnetic resonance imaging medicine.disease Magnetic Resonance Imaging 030220 oncology & carcinogenesis Concomitant Nephrogenic systemic fibrosis Hemodialysis business medicine.drug |
| Zdroj: | Abdominal radiology (New York). 46(8) |
| ISSN: | 2366-0058 |
| Popis: | To assess the risk of nephrogenic systemic fibrosis (NSF) in patients with renal impairment undergoing gadoxetic acid-enhanced magnetic resonance imaging. This retrospective study included patients who had an estimated glomerular filtration rate (eGFR) below 60 mL/min per 1.73 m2 or had undergone dialysis around the time of gadoxetic acid exposure from January 2010 to November 2019. All patients received at least one intravenous injection of gadoxetic acid at a fixed dose of 2.5 mmol. The primary endpoint was the development of NSF after exposure to gadoxetic acid based on Girardi’s clinicopathological scoring system. A total of 204 patients with renal impairment received 424 injections of gadoxetic acid, of which 131 and 54 had an eGFR of 30–59 and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink